Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
R Roskoski Jr - Pharmacological Research, 2022 - Elsevier
Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
R Roskoski Jr - Pharmacological Research, 2022 - europepmc.org
Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
R Roskoski Jr - Pharmacological research, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …
[引用][C] Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
R Roskoski - Pharmacological Research, 2022 - cir.nii.ac.jp
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous
leukemia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
leukemia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …